There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apogee Therapeutics, Inc. (APGE – Research Report), SAGE Therapeutics (SAGE – Research Report) and Aerovate Therapeutics (AVTE – Research Report) with bullish sentiments.
Apogee Therapeutics, Inc. (APGE)
BTIG analyst Julian Harrison reiterated a Buy rating on Apogee Therapeutics, Inc. yesterday and set a price target of $81.00. The company’s shares closed last Monday at $65.00, close to its 52-week high of $72.29.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Apogee Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $89.00.
See the top stocks recommended by analysts >>
SAGE Therapeutics (SAGE)
In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on SAGE Therapeutics, with a price target of $29.00. The company’s shares closed last Monday at $18.69, close to its 52-week low of $16.52.
According to TipRanks.com, Rama is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for SAGE Therapeutics with a $25.50 average price target.
Aerovate Therapeutics (AVTE)
Wells Fargo analyst Tiago Fauth maintained a Buy rating on Aerovate Therapeutics today and set a price target of $35.00. The company’s shares closed last Monday at $26.95, close to its 52-week high of $28.39.
According to TipRanks.com, Fauth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Aerovate Therapeutics is a Strong Buy with an average price target of $50.00, which is an 88.6% upside from current levels. In a report released yesterday, Jefferies also initiated coverage with a Buy rating on the stock with a $65.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APGE:
- Apogee Therapeutics Launches Innovative Antibody Clinical Trial
- Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
- Four new option listings on March 20th
- Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
- Apogee Therapeutics 6.77M share Secondary priced at $62.00
